News Archive

22 August 2007

New healthcare technology development project launched to improve patient outcome and the success rate of haematopoietic stem cell transplants (HSCT)

€3.5 million research and development programme is launched today to improve the success rate of stem cell transplants, including bone marrow transplants for Leukaemia patients. Professor Anne Dickinson, Haematological Sciences, Newcastle University, leads the programme in partnership with a consortium of 13 leading European clinical research institutes and biotech firms.

Known as StemDiagnostics, the consortium will aim to identify new bio-markers (indicators of transplant rejection and clinical complications) and develop medical diagnostic tests that will help practitioners to improve the success rate of allogeneic haematopoietic stem cell transplants (HSCT), treatments for life threatening medical conditions and cancers such as leukaemia, lymphoma and inherited immune disorders.

Around 7,000 such transplants take place throughout Europe each year, but the survival rate is low (40 – 60 per cent) and decreases rapidly with patient age. The application of HSCT therapy is also hampered by the lack of suitable matched donors: only 25 –30 per cent of patients find a compatible sibling donor.

Such transplants involve the use of bone marrow, peripheral blood stem cells and umbilical cord blood as stem cell sources.

The project, which follows 3 year’s research by Professor Dickinson and the Consortium, aims to develop tests with the use of the latest bionano and lab-on-a-chip techniques provided by SMEs such as Orla Protein Technologies, also based in North East England.

Professor Anne Dickinson, commented: “The project is the first of its kind to bring together research looking at a variety of different biomarkers – or indicators of post transplant complications. These include DNA and proteins. From this work, we hope to be able to develop new diagnostic tools using genomics, proteomics, in vitro bioassays and biochips, to aid in earlier clinical intervention by predicting any complications which may arise in our bone marrow transplant patients.”

StemDiagnostics will develop new proteomic, biological and genomic tests for predicting patient response prior to transplant and subsequently for monitoring of patient response to novel therapeutics for the most severe complication of HSCT – graft versus host disease (GvHD). The consortium aims to bring to the clinic the next generation of diagnostics tests for use in HSCT.
To meet this challenge, StemDiagnostics brings together five of European’s leading small and medium-sized enterprises (SMEs) with expertise in genomic and proteomic testing, diagnostic assay development and biochips, with clinical partners selected for their world-leading research in HSCT and access to clinical samples and patient groups. The SMEs include Mosaiques Diagnostics, Multimmune, IMGM Laboratories, Apotech and Orla Protein Technologies.

The programme is funded by the European Commission to the tune of €2.5M over next three years, through the EU Sixth Framework Programme under the Life Sciences and Health theme. The consortium provides for the remaining investment.

29/03/2007
Orla secure R&D grant to develop self-assembling antibody reagents